 |
|
 |
 |
LATEST NEWS
- 4Q, 2011: Notice-of-allowance for AGX-51 patent received from USPTO
- 3Q, 2011: AGX-51 demonstrates sufficiently promising activity in in-vitro tests at NCI to justify in-vivo studies scheduled to begin 4Q, 2011
- 2Q, 2011: AngioGenex and National Cancer Institute (NCI), National Institute of Health, sign agreement for NCI to evaluate AGX-51 in several of the institute's in-vitro and in-vivo cancer models
- New AGX Patent, Id1 Inhibitors Combined with Vacular Disruptors to Treat Cancer, Filed January, 2011
- Interview with AngioGenex CEO Appeared in November 2010 Issue of Wall Street Transcripts
- Phase 1 SBIR Grant Awarded September 2010 to AngioGenex by NCI/NIH to Further Develop the Use of Company's Lead Anti-Id1 Inhibitor with Taxanes Like TaxolTM to Treat Cancer
|
|
|
|
 |
